SPECIALTY GUIDELINE MANAGEMENT

MULPLETA (lusutrombopag)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Mulpleta is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review for thrombocytopenia in chronic liver disease: pretreatment platelet count.

III. EXCLUSIONS

Coverage will not be provided for members with the following exclusion: concomitant use of Mulpleta with other thrombopoietin receptor agonists (e.g., Doptelet, Promacta, Nplate) or with spleen tyrosine kinase inhibitors (e.g., Tavalisse).

IV. CRITERIA FOR INITIAL APPROVAL

Thrombocytopenia in chronic liver disease

Authorization of 30 days may be granted for treatment of thrombocytopenia in members with chronic liver disease when both of the following criteria are met:

- 1. Member has an untransfused platelet count of less than 50 x 10⁹/L taken within 14 days of the request.
- 2. Member is scheduled to undergo a procedure.

V. CONTINUATION OF THERAPY

Thrombocytopenia in chronic liver disease

Continuation of therapy, defined as use beyond the initial approval for same procedure, is not approvable. All members (including new members) requesting authorization due to newly scheduled procedure must meet all initial authorization criteria.

VI. REFERENCES

Mulpleta 2990-A SGM P2021.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



1. Mulpleta [package insert]. Florham Park, NJ: Shionogi Inc.; April 2020.

Mulpleta 2990-A SGM P2021.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

